Contribute Try STAT+ Today

Amid ongoing concern about the use of patient assistance programs by the pharmaceutical industry, two lawmakers want the Inspector General of the Department of Health and Human Services to update its oversight and require more disclosure from the foundations about their operations.

In arguing their case, the lawmakers maintained that some drug makers game the system by finding ways to boost sales of their own medicines while also benefiting from tax breaks. At the same time, they contended that programs favor expensive brand-name medicines over lower-cost generics and sometimes fail to help patients with the most need.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • An astute but troubling observation -“97% — required insurance coverage for eligibility” One would think the uninsured would require the most assistance? (Assuming they have fallen through the cracks rather than willfully being uninsured as a protest against the ACA.)

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy